

JAMES L. GULLEY, M.D., Ph.D., F.A.C.P.



Home

Office

10 Center Dr 8B08
Bethesda, MD 20892
Voice: (301) 435-2956
Fax: (301) 496-2756

**PRESENT ACADEMIC
POSITIONS**

Co-Director, Clinical Trials Group, Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. December 2001 to present.

Staff Clinician and Clinical Investigator, Vaccine Clinical Research Section, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. December 2001 to present.

Attending Physician and Clinical Investigator, Genitourinary Malignancies Clinical Research Section, Medical Oncology Clinical Research Unit, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD. July 2001 to present.

Adjunct Professor, School of Dentistry
Loma Linda University, Loma Linda, CA
January 1, 2003 to present

Member of the Genitourinary Malignancies Faculty, Center for Cancer Research, NCI, Bethesda, MD. July 2001 to present.

Member of the Gastrointestinal Malignancies Faculty, Center for Cancer Research, NCI, Bethesda, MD. March 2003 to present.

Member, Vaccine Working Group, Center for Cancer Research, NCI, Bethesda, MD. July 1999 to present.

Member, Immunology Faculty, Center for Cancer Research, NCI, Bethesda, MD. September 2002 to present.

Gulley Curriculum Vitae

PREVIOUS POSITIONS

July 2000-December 2001. Senior Clinical Fellow,
Laboratory of Tumor Immunology and Biology,
Center for Cancer Research, National Cancer Institute,
National Institutes of Health, Bethesda, MD

July 1998-June 2000. Clinical Fellow, Medicine Branch,
Division of Clinical Science, National Cancer Institute,
National Institutes of Health, Bethesda, MD.

HOSPITAL APPOINTMENTS

Staff Clinician, Warren Grant Magnuson Clinical
Center National Cancer Institute, National Institutes of Health
Bethesda, MD 20892 ---

Staff Physician, National Naval Medical Center
Bethesda, MD 20889 ---

Staff Physician, Walter Reed Army Medical Center
Washington, DC 20307 ---

PROFESSIONAL TRAINING

National Cancer Institute, Bethesda, MD
Medical Oncology Fellowship, completed --.
Board Certified ---.

Emory University, Atlanta, GA
Internal Medicine Residency, completed --.
Board Certified ---.

CLINICAL RESEARCH

Protocol Chairperson: [NCI 00-C-0154](#) "A Randomized
Phase II Study of a PSA-Based Vaccine in Patients with
Localized Prostate Cancer Receiving Standard Radiotherapy."

Principal Investigator: [NCI 02-C-0179](#) "Collection of Blood
from Patients with Cancer."

Protocol Chairperson [NCI 03-C-0176](#) "A phase I/II pilot
study of sequential vaccinations with rFowlpox-PSA(L155)-
TRICOM (PROSTVAC-F/TRICOM) alone, or in
combinations with rVaccinia-PSA(L155)-TRICOM
(PROSTVAC-V/TRICOM), and the role of GM-CSF, in
patients with prostate cancer."

Medically Responsible Investigator: [NCI 02-C-0083](#) "A
Multidose Phase I Study of Oral CC5013, a Thalidomide
Derivative, in Patients with Refractory Metastatic Cancer."

Associate Investigator: [NCI 00-C-0137](#) "A Randomized
Phase II Study of Either Immunotherapy with a Regimen of

Recombinant Pox Viruses that Express PSA/B7.1 + Adjuvant GM-CSF & IL-2 or Hormone Treatment with Nilutamide in Patients with Hormone Refractory Prostate Cancer and no Radiographic Evidence of Disease.”

Associate Investigator: [NCI 00-C-0080](#) “A Double Blind Randomized Crossover Phase III Study of Oral Thalidomide versus Placebo in Patients with Stage D0 Androgen Dependent Prostate Cancer Following Limited Hormonal Ablation.”

Associate Investigator: [NCI 00-C-0033](#) “A Randomized Phase II Trial of Weekly Docetaxel Plus Thalidomide Versus Weekly Docetaxel in Metastatic Androgen Independent Prostate Cancer.”

Associate Investigator: [NCI 00-C-0052](#) “A Randomized Phase II Study of High Dose Ketoconazole Plus Alendronate Versus High Dose Ketoconazole in Patients with Androgen Independent Metastatic Prostate Cancer.”

Associate Investigator: [NNMC B98-006](#) “Multicenter Prostate Cancer Database for the Center for Prostate Disease Research (CPDR) with Patterns of Care, Outcomes, and Prognostic Analysis.”

Associate Investigator: [NCI 91-C-0014](#) “A phase II trial of leuporlide + flutamide + suramin in untreated poor prognosis prostate carcinoma.”

Associate Investigator: [NCI 02-C-0149](#) “A Phase I Trial of High Dose Ketoconazole Plus Weekly Docetaxel in Metastatic Androgen Independent Prostate Cancer.”

Associate Investigator: [NCI 01-C-0256](#) Phase I Trial of 2-Methoxyestradiol (2ME2), (NSC-659853) an Angiogenesis Inhibitor, in Patients with Solid Tumors

Associate Investigator: [NCI 02-C-0218](#) A Pilot Trial of Concurrent docetaxel and a Pox Vector PSA Vaccine Followed by docetaxel in Metastatic Androgen Independent Prostate Cancer

Associate Investigator: [NCI 03-C-0005](#) A Pilot Study of Sequential Vaccinations With Recombinant Vaccinia-CEA(6D)-TRICOM, and Recombinant Fowlpox-CEA(6D)-TRICOM (B7.1/ICAM-1/LFA-3) With Sargramostim (GM-

CSF), In Conjunction With Standard Adjuvant Chemotherapy in High Risk Breast Cancer Patients

Associate Investigator: [NCI-02-C-0284](#) Phase II Pilot Study of Monoclonal Antibody CTLA-4 in Patients With Follicular or Mantle Cell Lymphoma, Colon Cancer, or Prostate Cancer Refractory to Vaccine Therapy.

Associate Investigator: [03-C-0157](#) A Phase II Study of perifosine in Patients with Metastatic Androgen Independent Prostate Cancer.

Associate Investigator: [04-C-0132](#) A Phase II Trial Combining Estramustine, Docetaxel and Thalidomide in Patients with Androgen-Independent Metastatic Prostate Cancer.

Principal Investigator: [CTEP 6439](#) A Pilot Trial of a CEA-TRICOM based vaccine and liver radiation with or without celecoxib, in patients with CEA positive tumors and liver metastasis. CTEP/PRMC/IRB approved

Principal Investigator: [CTEP 6536](#) An open label pilot study to evaluate the safety and tolerability of PANVAC™-VF in combination with GM-CSF in patients with metastatic colorectal adenocarcinoma. CTEP/PRMC approved

Protocol Chairman: [CTEP 6066](#) A Phase I Feasibility Study of Novel Intraprostatic PSA Based Vaccine in Patients with Advanced Prostate Cancer. CTEP approved September 27, 2002. MOCRU approved

Protocol Chairman: [CTEP 6439](#) A Pilot trial of recombinant fowlpox (rF)-CEA(6D)-TRICOM, recombinant vaccinia (rV)-CEA(6D)-TRICOM, and rF-GM-CSF in combination with combined chemotherapy / radiotherapy in patients with unresectable stage III non-small cell lung cancer. CTEP approved June 20, 2003.

**BASIC SCIENCE
RESEARCH**

Conducting research in the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, at the National Cancer Institute under Dr. --- and Dr. ---. July 1999 to present.

Gulley Curriculum Vitae

EDUCATION

Loma Linda University, Loma Linda, CA
Medical Scientist Training Program

M.D., ---

Ph.D., Microbiology, ---

Mentor: ---

Research in tumor immunology

Southern College of Seventh-day Adventists, Collegedale, TN

B.A., Chemistry

Graduated *Magna Cum Laude* and Southern Scholar

CERTIFICATIONS

Medical license: State of Georgia, ---

Diplomate of the National Board of Medical Examiners

Diplomate in Internal Medicine, American Board of Internal
Medicine

Diplomate in Medical Oncology, American Board of Internal
Medicine

Medical license: State of Maryland, ---

DEA registration # ---

Advanced Cardiac Life Support

Basic Cardiac Life Support

LEADERSHIP

Co-founder of the Microbiology Student Association, Loma
Linda CA. ---.

Clinical Co-chair of FelCom, the National Institutes of Health
Fellows Committee that represents over 3,500 postdoctoral
and clinical fellows at the NIH. March 2000-July 2001.

Chair, Distinguished Clinical Teachers Award committee,
FelCom, National Institutes of Health, March 2000-December
2001.

Member, NIH Fellows Committee Mentoring Subcommittee,
National Institutes of Health, May 2000-present.

Member, NIH Fellows Committee Publicity Subcommittee,
National Institutes of Health, March 2000-July 2001.

Member, Curriculum Committee, Medical Oncology Clinical
Trials Unit, Medical Oncology Training Program, CCR, NCI,
NIH, 2001 to present.

Chaired the first NCI working group convened to design 3
prospective, randomized controlled trials in prostate cancer
patients using PSA-TRICOM vaccines, July 18-19, 2002.

Gulley Curriculum Vitae

Member, Committee on Scientific Conduct and Ethics,
National Institutes of Health, December 2003 to present.

AWARDS / HONORS

Outstanding Freshman Award, "In recognition of
academic excellence," Southern College
CRC Press Freshman Chemistry Achievement Award
Magna Cum Laude, Southern College
Southern Scholar, Southern College
Medical Scientist Training Program, Loma Linda
University
1993 Selma Andrews Award, Loma Linda University
1993 Who's who of American Inventors
Resident Achievement Award "For Excellence in
Internal Medicine," Emory University
Offered position as Chief Resident of Internal Medicine,
Emory University
2000 AACR/ASCO Methods in Clinical Research awardee
Senior Fellowship Training Award, NCI, NIH
2001 Merit Award, American Society of Clinical Oncology
2001 Physicians Recognition Award, American Medical
Association
2001 NCI Departmental Award
2003 NCI Departmental Award
2003 NCI Group Merit Award "For major contributions to the
field of cancer immunotherapy"

GRANTS

DOD PC010488 Grant for "A Randomized Phase II Study of
a PSA-Based Vaccine in Patients with Localized Prostate
Cancer Receiving Standard Radiotherapy."

TEACHING

2001 to present NCI clinical center inpatient attending 1
month a year.

2001 to present National Naval Medical Center consult
attending 1 month a year.

2001 to present National Naval Medical Center clinic
attending 1 month a year.

2001 to present Attending in the NCI clinical center Prostate
Cancer Clinic 1 day per week

2001 to present Attending in the National Naval Medical
Center Prostate Cancer Clinic 2 days a week (medical
oncology and Center for Prostate Disease Research clinics).

2001 Department of Pharmacology, "Cancer Chemotherapy"

Gulley Curriculum Vitae

Taught medical students at the Uniformed Services University of the Health Sciences, Bethesda, MD 20814. Spring 2001.

2001 NIH Office of Education sponsored workshop for summer students. "How to Become a Member of the Next Generation of Biomedical Scientists." One of three panelists in a two-hour discussion. July 19, 2001.

2001 National Naval Medical Center televised panel discussion on prostate cancer issues and treatment, one of five panelists. Sept 4, 2001.

2002 Wrote questions for the American Board of Internal Medicine Board Certification Examination

INVITED LECTURES

"Immunotherapy of Prostate Cancer" Grand Rounds (CME credit given), Suburban Hospital, Bethesda, MD 8:00-9:00am, January 19, 2001.

"Tumor Immunotherapy" lecture given to clinical researchers at the National Naval Medical Center, 2:00-3:00 pm, April 10, 2001.

"Prostate Cancer and Clinical Trials at the National Cancer Institute" Lecture to the Andrews Air Force Base prostate cancer support group, 6:00-7:00 pm, May 1, 2001.

"Immunotherapy of Prostate Cancer" Grand Rounds, Doctor's Community Hospital, Prince George's County, MD (CME credit given)
12:00-2:00 pm, May 31, 2001.

"Immunotherapy of Prostate Cancer" Winship Cancer Institute Director's Seminar, Emory University, Atlanta, GA. 4:00-5:00pm June 28, 2001.

"Treatment of Advanced Prostate Cancer" Prostate Cancer Support Group sponsored by National Naval Medical Center and the American Cancer Society, National Naval Medical Center, October 26, 2001.

["Cancer Vaccines: A Translational Research Initiative"](#)
National Institutes of Health Bench to Bedside Grand Rounds (CME credit given), 12:00-1:00 pm, January 30, 2002.

"Vaccines for cancer: What we have learned and where we are going." E.O. Grundset lecture series for the Biology/Allied

Gulley Curriculum Vitae

Health Dept., Southern Adventist University, Collegedale, TN.
7:30-8:30 pm, March 21, 2002.

“Clinical Trials for Prostate Cancer at the National Cancer Institute.” Prostate Cancer Support Group sponsored by National Naval Medical Center and the American Cancer Society, National Naval Medical Center, 2:00-4:00pm, March 29, 2002.

“Prostate Cancer Vaccines at the NCI.” Southern Maryland Prostate Support Group, 7:00-9:00pm, May 14, 2002.

“Vaccine program at the NCI” An orientation session of NCI medical oncology fellows National Naval Medical Center, 2:30-3:00, July 5, 2002.

“Genitourinary Cancers.” A lecture to medical oncology fellows (from both the NCI and Walter Reed Army Medical Center), National Naval Medical Center, 9:00-10:00am, August 8, 2002.

“Pox viral Prostate Cancer Vaccines” A lecture to NCI medical oncology fellows National Naval Medical Center, 9:00-10:00am, August 23, 2002.

“Immunology and tumor immunotherapy” A lecture given to clinical researchers at the National Naval Medical Center, 2:00-3:00 pm, February 25, 2003.

“Osteoporosis and Prostate Cancer.” Prostate Cancer Support Group sponsored by National Naval Medical Center and the American Cancer Society, National Naval Medical Center, 1:00-2:30pm, February 28, 2003.

“Development of Prostate Cancer Vaccines.” A lecture given to the Genitourinary Malignancies Faculty, National Cancer Institute, Warren Grant Magnuson Clinical Center, 4:00-5:00 p.m., May 6, 2003.

“Osteoporosis and Prostate cancer” Prostate Cancer Support Group sponsored by the American Cancer Society, Winchester Medical Center, Winchester, VA, 7:00-9:00pm, July 1, 2003.

“Development of Prostate Cancer Vaccines.” A lecture given to the basic science faculty and staff at the Center for Molecular Biology and Gene Therapy at Loma Linda

Gulley Curriculum Vitae

University, Loma Linda, CA from 4:00-5:00 on August 7, 2003.

“Vaccines for Cancer.” A lecture given to the senior dental students, faculty and staff at the School of Dentistry at Loma Linda University, Loma Linda, CA from 9:00-10:00 on August 8, 2003.

“Prostate Cancer Clinical Trials at the NCI.” A lecture for the Anne Arundel Medical Center Prostate Cancer Support Group at Anne Arundel Medical Center from 7:30-9:00 pm on September 9, 2003.

“Development of Prostate Cancer Vaccines.” A lecture at the Medical Grand Rounds at the University of Nebraska School of Medicine, from 12:00-1:00 on September 29, 2003.

“Prostate Cancer Clinical Trials at the NCI.” A lecture for the Suburban Medical Center Prostate Cancer Support Group at Suburban Medical Center from 7:00-9:00 pm November 17, 2003.

“Osteoporosis and Prostate cancer” A CME lecture sponsored by Doctor’s Community Hospital, held at Ristorante Tragara, Bethesda, MD, December 15, 2003.

“Vaccine Related Clinical Trials” A lecture to the Genitourinary Malignancies Faculty at the National Cancer Institute, Bethesda, MD, January 6, 2004.

“Prostate Cancer and Bone Disease” A CME lecture for the Walter Reed Army Medical Center Medical Oncology Fellows and Staff, Washington, DC, February 20, 2004.

“Vaccine and Radiation for localized Prostate Cancer.” A lecture for the Spring 2004 NCI CTEP Early Drug Development Meeting, Bethesda, MD, February 25, 2004

“Vaccine Therapies: Prostate Cancer.” A CME lecture scheduled sponsored by the Doctors Community Hospital, the Metropolitan Ambulatory Urologic Institute and the Genitoruriary Malignancies Faculty, Bethesda Marriott, Bethesda, MD, March 13, 2004.

“Prostate Cancer Clinical Trials at the NCI.” A lecture for the Man-To-Man Prostate Cancer Support Group at Regional

Gulley Curriculum Vitae

Cancer Therapy Center, Frederick, MD from 6:30-7:30 pm
March 24, 2004.

VOLUNTEER

“Medical School for Junior High.” Discussion and role-playing for 7th and 8th graders. John Nevins Andrews Elementary School, Takoma Park, MD, 8:45-9:50am, April 26, 2002.

“Immunology for 7th Graders.” Discussion and role-playing in immunology for 7th graders. Sligo Adventist Elementary School, Takoma Park, MD. 9:30-10am May 24, 2002.

“Immunology for 8th Graders.” Discussion and role-playing in immunology for 8th graders. Sligo Adventist Elementary School, Takoma Park, MD. 10-10:30am May 24, 2002.

Medical Oncology Attending Physician for the TASC (Take a Scientist to the Clinic) Program, National Institutes of Health.

Judge for 8th grade (individual) and 6th-8th grade (overall) in the Sligo Adventist School Science Fair on April 15, 2003.

MEDIA INTERVIEWS

“Prostate Cancer” one of a 5 member panel of experts discussing issues relating to prostate cancer for the National Naval Medical Center television series.

”Choices: treatments for prostate cancer.” By Ellen Maurer, *The Journal*, National Naval Medical Center’s official newspaper. September 6, 2001 Volume 13, No. 35 p3.

[Brian Reid](#) “AACR: New Vaccine Plus Radiotherapy Boosts T-cell Response in Prostate-Cancer Patients” July 15, 2003 DGDDispatch.

PRESS PUBLICATIONS

[Gulley J](#) “A Randomized Phase II Study of a PSA-Based Vaccine in Patients with Localized Prostate Cancer Receiving Standard Radiotherapy.” Prostate Cancer Hot Sheet, Us Too! International, May/June 2001.

[Gulley J et al.](#) “Translational Studies: Defining Strategies to Enhance the Potency of Cancer Vaccines. CCR Frontiers in Science, Vol 1 page 6-7., Feb 2002.

[Gulley J](#) “Protocol ID: 00-C-0154 Phase II study of radiotherapy with or without vaccine in patients with localized prostate cancer.” CCR Frontiers in Science, Vol 2 page 6, Sep 2003.

Gulley Curriculum Vitae

CONSULTANT / REVIEWER

Consultant, Prostate Clinical Advisory Board,
[Therion Biologics Corporation](#), Boston, MA 2001 to 2003.

Consultant and Member of the Lecture Bureau for Prostate Cancer, AstraZeneca LP.

Consultant, Immunology Devices Panel, Medical Devices Advisory Committee, Center for Devices and Radiological Health, Food and Drug Administration.

Special Consultant for Prostate Cancer from the National Cancer Institute to the United States Congress (Congressional Office Inquiries)

Chief judge to the Tumor Immunology and Therapy Study Section, Fellows Award for Research Excellence, NIH, 2001.

Scientist Reviewer for the Congressionally Directed Medical Research Programs, Prostate Cancer Research Program, Immunological Sciences, June 2003.

Wrote a requested narrative on Prostate Cancer Research for the NCI office of Budget and Financial Management to be used in the Congressional Appropriations process, January 2004.

MEMBERSHIP

Active Junior, American Society of Clinical Oncology
Active Member, American Association for Cancer Research
Active, International Society for Biological Therapy of Cancer
Affiliate, Society of Urologic Oncology
Affiliate, American Society for Therapeutic Radiology and Oncology
Affiliate, American Urological Association
Fellow, American College of Physicians / American Society of Internal Medicine
American Medical Association
American Association for the Advancement of Science
Associate, Southern Medical Association
Member, Adventist Professionals' Network
Member, Adventist International Medical Society
Member, Medical Reserves Corp
Member, Cancer Trials Support Unit
Member, Cancer and Leukemia Group B
Member, Immunology Interest Group, NIH
Member, Vaccine Working Group, NCI, NIH
Member, Vascular Biology Faculty, NCI, NIH

REVIEWS

Reviewed articles for journals including *Clinical Cancer Research*, *Current Opinions in Molecular Therapeutics*, *Emerging Therapeutic Targets*, *Expert Opinion on Biologic Therapy*, *Journal of the National Cancer Institute*, *Nature Medicine*, *Neoplasia*, *Prostate Cancer and Prostatic Diseases*, *The Journal of Alternative and Complementary Medicine*, and *The Oncologist*.

Bibliography

PEER REVIEWED PUBLICATIONS

1. **Gulley J**, Arlen P and Dahut W. "Treating systemic prostate cancer: Emerging targets and therapies" *Emerging Therapeutic Targets* (2000) 4(6): 751-763.
2. Dahut W, Fedenko K, Noone M, Arlen P, **Gulley J**, Pluda J, and Figg W.D. "A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen independent prostate cancer." *Advances in Prostate Cancer*, March 2001, Vol. 5, No. 1 pages 8-10.
3. Zhu M, Terasawa H, **Gulley J**, Panicali D, Arlen P, Schlom J, and Tsang K. "Enhanced activation of human T Cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in human dendritic cells." *Cancer Research*, (2001) May 1;61(9):3725-34. [\[PubMed\]](#)
4. VonMehren M, Arlen P, **Gulley J**, Rogatko A, Cooper HS, Meropol NJ, Alpaugh RK, Davey M, McLaughlin S., Beard MT, Tsang KY, Schlom J, and Weiner LM. "The influence of GM-CSF and Prior Chemotherapy on the Immunologic Response to a Vaccine (ALVAC-CEA B7.1) in Patients with Metastatic Carcinoma." *Clinical Cancer Research* (2001) May 7(5): 1181-1191. [\[PubMed\]](#)
5. Figg WD, Arlen P, **Gulley J**, Fernandez P, Noone M, Fedenko K, Hamilton M, Parker C, Kruger EA, Puda J, Dahut WD. "A randomized phase II trial of docetaxel (Taxotere) plus thalidomide in androgen independent prostate cancer." *Seminars in Oncology* 28:(4) 62-66 Suppl. 15 AUG 2001. [\[PubMed\]](#)
6. Tsang KY, Zhu M, Even J, **Gulley J**, Arlen P and Schlom J. "The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells." *Cancer Res.* 2001 Oct 15;61(20):7568-76. [\[PubMed\]](#)
7. Terasawa H, Tsang K, **Gulley J**, Arlen P, Schlom J. "Identification and characterization of a human agonist epitope of human prostate-specific antigen." *Clinical Cancer Research* 2002 Jan;8(1):41-53. [\[PubMed\]](#)

Gulley Curriculum Vitae

8. **Gulley J**, Figg WD, Dahut WL. Docetaxel plus thalidomide in a patient with androgen-independent prostate cancer. *Case Studies in Prostate Cancer* March 2002, 1(1):1-7.
9. **Gulley J**, and Dahut W. Novel Clinical Trials in Androgen Independent Prostate Cancer. *Clinical Prostate Cancer* 2002 June 1(1):51-57.
10. **Gulley J**, Chen AP, Dahut W, Arlen PM, Bastian A, Steinberg S, Tsang K, Panicali D, Poole D, Schlom J, and Hamilton, JM. "Phase I Study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in Patients with Metastatic Androgen Independent Prostate Cancer." *The Prostate* 2002 53(2):109-117. [\[PubMed\]](#)
11. Arlen PM, Figg WD, **Gulley J**, Cox MC, Linehan WM, Dahut W. "NCI intramural approach to advanced prostate cancer." *Clinical Prostate Cancer* 2002 1(3):153-162.
12. **Gulley J**, Figg WD, Dahut WL. Treatment Options for Androgen Independent Prostate Cancer. *Clinical Advances in Hematology and Oncology* 2003 1(1):49-57.
13. Horne MK, Figg WD, Arlen PM, **Gulley J**, Parker C, Lakhani N, Parnes H, and Dahut WD. Increased incidence of venous thromboembolism with the combination of docetaxel and thalidomide in patients with metastatic androgen-independent prostate cancer. *Pharmacotherapy* 2003 Mar 23(3):315-318. [\[PubMed\]](#)
14. Behrens RJ, **Gulley JL**, and Dahut WL. Docetaxel Pulmonary Toxicity During Prostate Cancer Treatment. *Am J Therapeutics* 2003 May-Jun;10(3):228-32. [\[PubMed\]](#)
15. Arlen PM, **Gulley JL**, Tsang K, and Schlom J. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer. *Expert Review of Vaccines*, 2003, 2(4):483-493. [\[PubMed\]](#)
16. Rutter JL, Rao RS, Bouchelet I, Doros G, Green H, **Gulley JL**, Koblinski J, Lundberg M, Stolzenberg-Soloman R, Wheelock R, Williams W, Wolfsberg T, Graubard B, Hartge P, Wacholder S, and Schwartz JP. Survey of Mentoring Experiences of NIH Postdoctoral Fellows. http://felcom.nih.gov/Mentoring/Mentor_revised_081403.pdf
17. **Gulley J**, Arlen PM, Palena C, Schlom J, and Tsang K. Optimization of the ELISPOT assay using Fowlpox vector encoded gene for human B7.1 (rF-B7.1) Infected Antigen Presenting Cells. *Journal of Immunologic Methods*, 2003 Aug 1;279(1-2):183-92. [\[PubMed\]](#)

Gulley Curriculum Vitae

18. Tohnya T, Ng S, Dahut W, Wright J, Arlen P, **Gulley J**, Parker C, Zeldis J, Figg W. A Phase I Study of Oral CC-5013, RevimidTM, a Thalidomide Derivative in Patients with Refractory Metastatic Cancer. *Clinical Lymphoma*, March 2004.
19. Leonard GD, Dahut WL, **Gulley JL**, Arlen PM, and Figg WD. Docetaxel and thalidomide as a treatment option in androgen independent prostate cancer. *Reviews in Urology*, 2003; 5 (suppl 3): S65-S70.
20. Posadas EM, Dahut WL, **Gulley J**. The Emerging Role of Bisphosphonates in Prostate Cancer. *Am J Therapeutics*, 2004, 11(1):60-73. [\[PubMed\]](#)
21. **Gulley J.L.**, Dahut W.L. "Novel approaches to treating the asymptomatic hormone refractory prostate cancer patient." *Urology*, 62(Suppl 6B): 147-154, 2003. [\[PubMed\]](#)
22. Arlen PM, **Gulley JL**. Therapeutic Vaccines for Colorectal Cancer: A Review of Clinical Data. *Am J Cancer*, in press [\[PubMed\]](#).
23. Tsang K, Palena C, **Gulley J**, Arlen P, and Schlom J. Identification and characterization of a human cytotoxic T-lymphocyte epitope and agonist epitope from the non-variable number of tandem repeat sequence of MUC-1 tumor antigen. *Clin Ca Res*, 2004 Mar 15;10(6):2139-49. [\[PubMed\]](#)
24. Pending publication deleted.
25. Pending publication deleted.
26. Pending publication deleted.
27. Pending publication deleted.
28. Pending publication deleted.
29. Pending publication deleted.
30. Pending publication deleted.
31. Pending publication deleted.
32. Pending publication deleted.
33. Pending publication deleted.
34. Pending publication deleted.

Gulley Curriculum Vitae

BOOKS / CHAPTERS

1. **Gulley J.** *The production and characterization of a monoclonal antibody to a naturally occurring aminomalonic acid epitope and a comparison with an antibody to a synthetically derived aminomalonic acid epitope.* Proquest Co, ©1994, p 1-260.
2. **Gulley J,** and Takimoto C. “Pancreatic Cancer.” *The Bethesda Handbook of Clinical Oncology*, J Abraham and C Allegra eds. Lippincott Williams and Wilkins, ©2001 p107-112.
3. **Gulley J,** Arlen P, and Schlom J. “Chapter 13: Pox Viral Vaccines.” M. Morse, T Clay and H.K. Lyster eds. *Handbook of Cancer Vaccines*, Humana Press Inc., Totowa, N.J. ©2004, p 175-191.
4. Odogwu L, **Gulley J,** Arlen P, and Marshall JL. “Vaccines for the treatment of cancer.” *Pharmacokinetics and Pharmacodynamics of Anti-Cancer Drugs*. Figg W and McLeod H eds. The Humana Press. *In Press*.
5. **Gulley JL** and Dahut WL. “Chapter 11: Novel schedules of Hormone Therapy for Prostate Cancer.” Devita V, Hellman S, and Rosenberg S eds. *Progress in Oncology*, Jones and Bartlett Publishers, scheduled for publication 2004. *In Press*, p234-251.
6. Pending publication deleted.
7. **Gulley J,** Kim G. and Allegra C. “Pancreatic Cancer.” *The Bethesda Handbook of Clinical Oncology*, J Abraham, **J Gulley** and C Allegra eds. Lippincott Williams and Wilkins. *In Press*.
8. Arlen PM and **Gulley JL.** “Hematopoietic Growth Factors” *The Bethesda Handbook of Clinical Oncology*, J Abraham, **J Gulley** and C Allegra eds. Lippincott Williams and Wilkins. *In Press*.
9. **Gulley JL** and Dahut WL. “Prostate Cancer” *The Bethesda Handbook of Clinical Oncology*, J Abraham, **J Gulley** and C Allegra eds. Lippincott Williams and Wilkins. *In Press*.
10. Pending publication deleted.

ABSTRACTS

1. **Gulley J,** VanBuskirk J, Kirsch WM, and Nehlsen-Cannarella S. “The production and characterization of a monoclonal antibody to a naturally occurring aminomalonic acid epitope.” *The Journal of Immunology*, Vol. 150, No. 8, Part II, April 15, 1993, 144A (815).

Gulley Curriculum Vitae

2. **Gulley J**, Kirsch W, Fowler S, and Nehlsen-Cannarella S. "Monoclonal antibodies to aminomalonic acid-containing epitopes from a human prostate carcinoma cell line (DU-145)." *The FASEB Journal*, Vol 6, No. 5, February, 1992, A1720 (4540).
3. Dahut W, Dyer V, Arlen P, **Gulley J**, Fedenko K, Chen C, Jones E, Premakumar A, Ando Y, Knopf K, Hamilton JM, and Figg WD. A randomized Phase II trial of Ketoconazole and Alendronate versus high dose Ketoconazole in androgen independent metastatic prostate cancer. *Journal of Urology*, American Urologic Association (AUA) 2000, 163(4): 1165a.
4. **Gulley J**, Dahut W, Chen A, Arlen P, Bastian A, Tsang K, Schlom J, Panicali D, and Hamilton M. "A phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with androgen independent prostate cancer (AIPC)." *Proceedings Am Soc Clin Onc* 2001, 20(1): 273a #1088. **Merit Award**
5. Arlen P, **Gulley J**, Schlom J, and Tsang K. "Optimization of the ELISPOT assay using fowlpox vector encoded gene for human B7.1 (rF-B7.1) infected antigen presenting cells (APC)." *Proceedings Am Soc Clin Onc* 2001, 20(1): 256a #1023.
6. Dahut W, Dyer V, Arlen P, **Gulley J**, Fedenko K, Chen C, Jones E, Premakumar A, Ando Y, Knopf K, Hamilton J, and Figg W. "A randomized phase II trial of ketoconazole (KT) and Alendronate (AL) versus ketoconazole in androgen independent prostate cancer (AIPC)." *Proceedings Am Soc Clin Onc* 2001, 20(1): 185a #737.
7. Marshall JL, Rizvi N, Fox E, Figueira M, Arlen P, **Gulley J**, Tsang K, Schlom J. A phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)- TRICOM and GM-CSF in patients with CEA expressing carcinomas. AACR-NCI-EORTC International Conference, 2001. 798a.
8. Y Liu, W D Figg, P Arlen, **J Gulley**, K Fedenko, SM Steinberg, M Lewis, C Chen, E Jones, Y Ando, and W L Dahut. "A Randomized Phase II Trial of Ketoconazole (KT) and Alendronate (AL) Versus Ketoconazole in Androgen Independent Prostate Cancer (AIPC)." 3rd North American Symposium on Bone Metastasis, April 26, 2002.
9. Palena CM, Arlen P, **Gulley J**, Schlom J, and Tsang KY. CDNA microarray analysis of gene expression profiles of a human CEA-specific T-cell line stimulated with a CEA peptide (CAP-1) and the agonist peptide (CAP1-6D). *Proc Am Assoc Ca Res* March 2002 43:323, #1603.
10. **Gulley J**, Dahut W, Arlen PM, Bastian A, Coleman N, Tsang K, Douglas R, Sullivan F, and Schlom J. A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy. *Proceedings Am Soc Clin Onc* 2002; A1814.

Gulley Curriculum Vitae

11. Dahut W, Arlen P, **Gulley J**, Parker C, Fedenko K, Noone M, Hamilton M, Chen C, Jones E, Linehan M, Pluda J, Figg WD. A Randomized Phase II Trial of Docetaxel Plus Thalidomide in Androgen-Independent Prostate Cancer. *Proceedings Am Soc Clin Onc* 2002; A730.
12. Philip M. Arlen, **James Gulley**, Laura Novik, J. Michael Hamilton, Anne Bastian, Dennis Panicali, Claudia Palena, Kwong Y Tsang, Jeffrey Schlom, William Dahut. A Randomized Phase II Trial of Either Vaccine Therapy (Recombinant Pox Viruses Expressing PSA and the B7.1 Costimulatory Molecule) Versus Hormone Therapy (Nilutamide) in Patients with Hormone Refractory Prostate Cancer and No Radiographic Evidence of Disease. *Proceedings Am Soc Clin Onc* 2002; A728.
13. John L Marshall, Philip M Arlen, Naiyer Rizvi, **James Gulley**, Evelyn Fox, Jimmy Hwang, Kwong Tsang, Jeffrey Schlom. A phase I study of sequential vaccinations with fowlpox-CEA (6D)-Tricom (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)-Tricom and GM-CSF in patients with CEA expressing carcinomas. *Proceedings Am Soc Clin Onc* 2002; A24.
14. Jane Carter, Kathy Fedenko, **James Gulley**, Phil M Arlen, Gregory Curt, William L Dahut, Catherine Parker. Beyond teratogenicity: the less common toxicities of thalidomide. *Proceedings Am Soc Clin Onc* 2002; A2894.
15. Claudia Palena, MingZhu Zhu, Phil Arlen, **James Gulley**, Jeffrey Schlom and Kwong Y. Tsang. "Enhanced activation of antigen-specific T cells via recombinant avipox vector-mediated expression of three costimulatory molecules (B7-1, ICAM-1 and LFA-3) in human B cells." *Proc. Am. Assoc. Cancer Res.* April, 2003, 44:650 A2850.
16. Mahesh Seetharam, Christopher S. D Lee, Patricia Kay Beetham, **James Gulley**, Philip Arlen, Jeffrey Schlom, Kwong Y Tsang. A novel protein-based immunoassay to monitor specific T-cell responses using monocytes as antigen presenting cells (APCs). *Proc. Am. Assoc. Cancer Res.* April 2003, 44:656 A2874.
17. Y Liu, W D Figg, P Arlen, **J Gulley**, K Fedenko, SM Steinberg, M Lewis, C Chen, E Jones, Y Ando, and W L Dahut. "A Randomized Phase II Trial of Ketoconazole and Alendronate Versus Ketoconazole in Androgen Independent Prostate Cancer." *Oncology*, April 2003 17(4) S3:40-41.
18. Philip M. Arlen, **James Gulley**, Laura Novik, J. Michael Hamilton, Steven Rucker, Anne Bastian, Dennis Panicali, Claudia Palena, Kwong Y Tsang, Jeffrey Schlom¹, William Dahut. A Randomized Phase II Trial of Either Vaccine Therapy (Recombinant Pox Viruses Expressing PSA and the B7.1 Costimulatory Molecule) Versus Hormone Therapy (Nilutamide) in Patients with Hormone Refractory Prostate Cancer and No Radiographic Evidence of Disease. *Proc. Am. Urol. Assn.* 2003.

Gulley Curriculum Vitae

19. **James L Gulley**, William D Figg, Jane Carter, Kathy Fedenko, Philip M Arlen, Maha Hussain, Daniel P. Petrylak, Oliver Sartor, Celestia Higano, and William L Dahut. A prospective analysis of the time to normalization of serum testosterone (T) following 6 months of androgen deprivation therapy in patients on a randomized Phase III clinical trial utilizing intermittent hormonal therapy. *Proc Am Soc Clin Onc* 2003. A1592.
20. Philip M. Arlen, **James Gulley**, Catherine Parker, Lisa Skarupa, Mary Pazdur, Dennis Panicali, Patricia Beetham, Claudia Palena, Kwong Y Tsang, Jeffrey Schlom, William Dahut. A Randomized Pilot Study of Concurrent Docetaxel Plus PSA Pox-Vaccine Versus Vaccine Alone in Metastatic Androgen Independent Prostate Cancer. *Proc Am Soc Clin Onc* 2003. A1701.
21. Yinong Liu, Tanyifor M. Tohnya, William D Figg, **James Gulley**, Phil M Arlen, Cathy Parker, Katherine Fedenko, Clara C. Chen, Elizabeth Jones, William L Dahut. Phase I study of Revimid (CC-5013), a thalidomide derivative in patients with refractory metastatic cancer. *Proc Am Soc Clin Onc* 2003. A927.
22. William D Figg, Yinong Liu, Milin R Acharya, **James L Gulley**, Phil M Arlen, Mary Lewis, John Wright, Howard Parnes, Clara Chen, Elizabeth Jones, William L Dahut. A phase I trial of high dose ketoconazole plus weekly docetaxel in metastatic androgen independent prostate cancer. *Proc Am Soc Clin Onc* 2003. A1731.
23. William L Dahut, Nehal Lakhani, Yinong Liu, **James Gulley**, Phil M Arlen, Miranda Raggio, John Wright, Clara Chen, Elizabeth Jones, William D Figg. A phase I study of 2-methoxyestradiol (2ME₂) in patients with solid tumors. *Proc Am Soc Clin Onc* 2003. A833.
24. J. Marshall, L. Odogwu, J. Hwang, E. Fox, S. Park, P. M. Arlen, **J. L. Gulley**, K. Tsang, J. Schlom. A phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM (B7.1/ICAM-1/LFA-3) alone, and sequentially with vaccinia-CEA (6D)-TRICOM and GM-CSF in patients with CEA-expressing carcinomas. *Proc Am Soc Clin Onc* 2003. A662.
25. **James L Gulley**, William D Figg, Jane Carter, Kathy Fedenko, Philip M Arlen, Maha Hussain, and William L Dahut. A prospective analysis of the time to normalization of serum testosterone following 6 months of androgen deprivation therapy in patients on a randomized Phase III clinical trial utilizing intermittent hormonal therapy. *Prostate Cancer and Prostatic Diseases*, 6(S1), pS12, 2003.
26. **James L. Gulley**, William Dahut, Philip M. Arlen, Anne Bastian, Steven Rucker, Jennifer Marte, Patricia Beetham, Dennis Panicali, Claudia Palena, Mahesh Seetharam, Kwong Tsang, Norman Coleman, Jeffrey Schlom. A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy. *Proc. Am. Assoc. Cancer Res.* July 2003. A LB172

Gulley Curriculum Vitae

27. Pending Abstract deleted.
28. **James L. Gulley**, William Dahut, Philip M. Arlen, Anne Bastian, Steven Morin, Jennifer Marte, Patricia Beetham, Kwong Tsang, Norman Coleman, Dennis Panicali, Jeffrey Schlom. A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy. 10th Annual CaP CURE (Prostate Cancer Foundation) meeting, September, 2003.
29. Philip M. Arlen, **James L. Gulley**, Catherine Parker, Lisa Skarupa, Mary Pazdur, Dennis Panicali, Patricia Beetham, Kwong Y Tsang, Jeffrey Schlom, William Dahut. A Randomized Pilot Study of Concurrent Docetaxel Plus PSA Pox-Vaccine Versus Vaccine Alone in Metastatic Androgen Independent Prostate Cancer (AIPC). AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, 2003. Abstract C96. Published as a Supplement to Clinical Cancer Research, Volume 9, Issue 16 (December 1, 2003).
30. **Gulley J.** "A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy." 4th Annual Society of Urologic Oncology meeting, Bethesda, MD, December 6, 2003.
31. Posadas EM, Trout A, Senderowicz AM, Figg WD, Lee M, Chung EJ, Trepel JB, **Gulley J**, Arlen PM, Kohler D, Steinberg SM, Fedenko KM, Wright JJ, Parnes HL, Dahut WL. A phase II trial of oral perifosine in patients with metastatic androgen-independent prostate cancer (AIPC). Society of Urologic Oncology, 2003 Annual Meeting, Bethesda, MD.
32. J. Gulley, P. Arlen, N. Todd, K. Camphausen, N. Coleman, J. Greiner, M. Chakraborty, J. Hodge, J. Schlom. "A phase I trial of a CEA-TRICOM vaccine and liver radiation with or without celecoxib in patients with CEA positive solid tumors metastatic to the liver." Program/Proceedings 2004 Gastrointestinal Cancer Symposium, Abstract 277, p178.
33. Philip M. Arlen, James L. Gulley, William Dahut, Lisa Skarupa, Mary Pazdur, Nushin Todd, Steve Morin, Dennis Panicali, Kwong Y Tsang, Jeffrey Schlom. "A Phase I Study of Sequential Vaccinations With Recombinant Fowlpox-PSA (L155)-TRICOM (rF) Alone, or in Combination with Recombinant Vaccinia-PSA (L155)-TRICOM (rV), and the Role of GM-CSF, in Patients (Pts) with Prostate Cancer." *Proc Am Soc Clin Onc* vol. 23, 2004.

PRESENTATIONS (International Meetings)

1. **Gulley J.** "A phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with androgen independent prostate cancer (AIPC)." A poster presentation to the 37th Annual meeting of the American Society of Clinical Oncology, San Francisco, CA, May, 2001. **Merit Award**

Gulley Curriculum Vitae

2. **Gulley J.** "Optimization of the ELISPOT assay using fowlpox vector encoded gene for human B7.1 (rF-B7.1) infected antigen presenting cells (APC)." A poster presentation to the 37th Annual meeting of the American Society of Clinical Oncology, San Francisco, CA, May, 2001.
3. **Gulley J.** "A Randomized Phase II Trial of Either Vaccine Therapy (Recombinant Pox Viruses Expressing PSA and the B7.1 Costimulatory Molecule) Versus Hormone Therapy (Nilutamide) in Patients with Hormone Refractory Prostate Cancer and No Radiographic Evidence of Disease. A poster presentation to the 38th Annual meeting of the American Society of Clinical Oncology, Orlando, FL, May, 2002.
4. **Gulley J.** "A phase I study of sequential vaccinations with fowlpox-CEA (6D)-Tricom (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)-Tricom and GM-CSF in patients with CEA expressing carcinomas." A poster presentation to the 38th Annual meeting of the American Society of Clinical Oncology, Orlando, FL, May, 2002.
5. **Gulley J.** "A prospective analysis of the time to normalization of serum testosterone (T) following 6 months of androgen deprivation therapy in patients on a randomized Phase III clinical trial utilizing intermittent hormonal therapy." A poster presentation at the American Society for Clinical Oncology, Chicago, IL on June 3, 2003.
6. **Gulley J.** "Androgen Receptor Axis in Hormone Refractory Prostate Cancer." An oral review of 8 selected articles given to the 3rd annual Innovators in Urology meeting, Amsterdam, Netherlands, 2:00pm, June 6, 2003.
7. **Gulley J.** "A prospective analysis of the time to normalization of serum testosterone (T) following 6 months of androgen deprivation therapy in patients on a randomized Phase III clinical trial utilizing intermittent hormonal therapy." A poster presentation given to the 3rd annual Innovators in Urology meeting, Amsterdam, Netherlands, 2:00pm, June 7, 2003.
8. **Gulley J.** "A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy." A poster presentation given to the 3rd annual Innovators in Urology meeting, Amsterdam, Netherlands, 2:00pm, June 7, 2003.
9. **Gulley J.** "A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy." A poster presentation to the American Association of Cancer Research, Washington, DC, July 13, 2003.
10. **Gulley J.** Invited to give a presentation to the 4th annual Innovators in Urology meeting, Vancouver, Canada, August 2004.

Gulley Curriculum Vitae

PRESENTATIONS (National Meetings)

1. **Gulley J.** “Monoclonal antibodies to aminomalonic acid epitope reactive to arterial and granuloma foam cells.” Poster presentation at Federation of American Societies for Experimental Biology, Georgia World Congress Center, Atlanta, GA, April 22, 1991.
2. **Gulley J.** “Isolation and characterization of aminomalonic acid enriched proteins from granuloma foam cells.” Poster presentation at Federation of American Societies for Experimental Biology, Georgia World Congress Center, Atlanta, GA, April 22, 1991.
3. **Gulley J.** “Monoclonal antibodies to aminomalonic acid-containing epitopes from a human prostate carcinoma cell line (DU-145).” Poster presentation at Federation of American Societies for Experimental Biology, Anaheim Convention Center, Anaheim, CA, April 8, 1992.
4. **Gulley J.** “The production and characterization of a monoclonal antibody to a naturally occurring aminomalonic acid epitope.” Poster presentation at The Joint Meeting of The American Association of Immunologists and The Clinical Immunology Society, Colorado Convention Center, Denver, CO, May 23, 1993.
5. **Gulley J.** “A Phase I Study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in Patients with Androgen Independent Prostate Cancer.” Poster Presentation to the 1st annual Society of Urologic Oncology, Natcher Building, NIH, Bethesda MD, Dec 2-3, 2000.
6. **Gulley J.** “A Phase I/II Trial of Mitoxantrone/Hydrocortisone plus Samarium-153 in Androgen Independent Prostate Cancer Metastatic to Bone.” Proposal for a new co-operative group trial. CALGB GU Core group meeting, Amelia Island, FL, Nov 16, 2001.
7. **Gulley J.** “A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy.” A poster presentation to the 10th Annual CaP CURE meeting, New York, NY, Nov 9, 2003.
8. **Gulley J.** “A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy.” An oral presentation to the 4th Annual Society of Urologic Oncology meeting, Bethesda, MD, December 6, 2003.
9. **Gulley J.** “A phase I trial of a CEA-TRICOM vaccine and liver radiation with or without celecoxib in patients with CEA positive solid tumors metastatic to the liver.” A poster presentation to the 1st Annual meeting, [Gastrointestinal Cancers Symposium](#), San Francisco, CA January 24, 2004.

Gulley Curriculum Vitae

PRESENTATIONS (Intramural / Regional meetings)

1. **Gulley J.** “Monoclonal antibodies to a human prostate cell line.” Poster presentation at Loma Linda University Annual Postgraduate Convention, Randall Visitors Center, Loma Linda, CA, February 23 and 24, 1992.
2. **Gulley J.** “A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy.” A slide presentation to the Laboratory of Tumor Immunology and Biology (LTIB), National Cancer Institute, Bethesda, MD, February 9, 2000.
3. **Gulley J.** “A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy.” A slide presentation to Therion Biologics Corporation/ LTIB meeting, Pooks Hill Marriot, February 11, 2000.
4. **Gulley J.** “A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy.” Poster presentation at the National Cancer Institute, Division of Basic Sciences, Postdoctoral Fellow Retreat, Fort Hood College, Frederick, MD June 13, 2000.
5. **Gulley J.** “A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy.” Poster presentation at the National Cancer Institute, Center for Cancer Research Fellows Symposium, NIH, Bethesda, MD April 6, 2001.
6. **Gulley J.** “A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy—trial update.” A slide presentation to the Laboratory of Tumor Immunology and Biology (LTIB), National Cancer Institute, Bethesda, MD, April 12, 2001.
7. **Gulley J.** “Overview of the pox-virus based vaccine clinical trials associated with the Laboratory of Tumor Immunology and Biology, CCR, NCI.” A slide presentation to the Laboratory of Tumor Immunology and Biology (LTIB), National Cancer Institute, Bethesda, MD, May 1, 2001.
8. **Gulley J.** “Activation of human T cells via avipox vector-mediated hyperexpression of a triad of costimulatory molecules in freshly isolated peptide pulsed human B cells.” A poster presentation to the Center for Cancer Research Postdoctoral & Trainees Assembly Retreat, June 12-13, 2001.
9. **Gulley J.** “A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy.” An oral presentation to the Center for Cancer Research Postdoctoral & Trainees Assembly Retreat, June 12-13, 2001.

Gulley Curriculum Vitae

10. **Gulley J.** "Clinical Vaccine Program: A Translational Initiative, from Bench to Bedside." A poster and oral presentation to the Laboratory of Tumor Immunology extramural site visit team (Dr. Jerome Ritz, Dr. Ralph Reisfeld, Dr. Esteban Celis, Dr. Mathew Cheever), October 4, 2001.
11. **Gulley J.L.** "Strategies for the Design and the Development of Prostate Cancer Vaccines." A poster presentation to the first Genitourinary Malignancies Faculty Retreat, Bethesda, MD, March 15, 2002.
12. **Gulley J.** "Overview of the orthopox-virus driven PSA based vaccine clinical trials associated with the Laboratory of Tumor Immunology and Biology, CCR, NCI." An oral presentation to the Laboratory of Tumor Immunology and Biology (LTIB), National Cancer Institute, Bethesda, MD, 10:00am-12:00pm, June 18, 2002.
13. **Gulley J.** "Overview of the orthopox-virus driven MUC-1 based and orthopox-virus intratumoral vaccine clinical trials associated with the Laboratory of Tumor Immunology and Biology, CCR, NCI." An oral presentation to the Laboratory of Tumor Immunology and Biology (LTIB), National Cancer Institute, Bethesda, MD, 12:30-2:00 pm, June 27, 2002.
14. **Gulley J.** "Overview of the orthopox-virus driven PSA based and orthopox-virus intratumoral vaccine clinical trials associated with the Laboratory of Tumor Immunology and Biology, CCR, NCI." An oral presentation to Therion Biologics Corporation, Cambridge MA, 1:00-3:00pm, June 28, 2002.
15. **Gulley J.** "Overview of the intramural vaccine clinical trials associated with the Laboratory of Tumor Immunology and Biology, CCR, NCI." An oral presentation to a joint meeting of the LTIB and Therion Biologics Corporation, Rockville, MD, 7:30-10:00am, October 11, 2002.
16. **Gulley J.** "Design, development and delivery of recombinant vaccines for the therapy of human carcinomas: a multi-institute programmatic effort." A poster presentation to the 7th annual NCI Combined Intramural Principal Investigator Retreat, Marriott's Westfields International Conference Center, Chantilly, Virginia, January 10, 2003.
17. **Gulley J.** "Intramural Clinical Trials" An oral presentation describing the 10 vaccine clinical trials ongoing or planned at the NCI, given to the Laboratory of Tumor Immunology and Biology (LTIB), National Cancer Institute, Bethesda, MD, 9:00-11:00am, March 20, 2003.
18. **Gulley J.** "A PSA-based vaccine in a randomized phase II study of patients with localized prostate cancer receiving standard radiotherapy." A poster presentation to the Center for Cancer Research, Bethesda, MD, 1:00-5:00 p.m., April 7, 2003.
19. **Gulley J.** "Overview of the pox-virus driven PSA based and pox-virus CEA based vaccine clinical trials associated with the Laboratory of Tumor Immunology and Biology, CCR, NCI." An oral presentation to Therion Biologics Corporation, Cambridge MA, 10:00-11:30am, May 8, 2003. **Gulley J.** "Overview of the pox-virus driven PSA based and pox-virus CEA / MUC-1 based vaccine clinical trials associated with the Laboratory of Tumor Immunology and Biology, CCR, NCI." An oral presentation to personnel from Therion Biologics Corporation and the LTIB, New York, NY, October 2, 2003. **Gulley J.** "Overview of the pox-virus driven PSA based and pox-virus CEA / MUC-1 based vaccine clinical trials associated with the Laboratory of Tumor Immunology and Biology, CCR, NCI." An oral presentation to LTIB-associated clinical trial investigators, New York, NY, October 4, 2003